BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29906468)

  • 1. Liver metabolomics in a mouse model of erythropoietic protoporphyria.
    Wang P; Sachar M; Guo GL; Shehu AI; Lu J; Zhong XB; Ma X
    Biochem Pharmacol; 2018 Aug; 154():474-481. PubMed ID: 29906468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.
    Barman-Aksözen J; C Wiek P; Bansode VB; Koentgen F; Trüb J; Pelczar P; Cinelli P; Schneider-Yin X; Schümperli D; Minder EI
    Dis Model Mech; 2017 Mar; 10(3):225-233. PubMed ID: 28093505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria.
    Wang P; Sachar M; Lu J; Shehu AI; Zhu J; Chen J; Liu K; Anderson KE; Xie W; Gonzalez FJ; Klaassen CD; Ma X
    Sci Adv; 2019 Sep; 5(9):eaaw6127. PubMed ID: 31555729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model.
    Abitbol M; Puy H; Sabaté JM; Guénet JL; Deybach JC; Montagutelli X
    Physiol Res; 2006; 55 Suppl 2():S93-101. PubMed ID: 17298226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metabolomic perspective of griseofulvin-induced liver injury in mice.
    Liu K; Yan J; Sachar M; Zhang X; Guan M; Xie W; Ma X
    Biochem Pharmacol; 2015 Dec; 98(3):493-501. PubMed ID: 26343413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria.
    Delaby C; Lyoumi S; Ducamp S; Martin-Schmitt C; Gouya L; Deybach JC; Beaumont C; Puy H
    Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):45-52. PubMed ID: 19268001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.
    Duchartre Y; Petit N; Moya C; Lalanne M; Dubus P; Verneuil Hd; Moreau-Gaudry F; Richard E
    J Hepatol; 2011 Jul; 55(1):162-70. PubMed ID: 21145811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
    Schmidt PJ; Hollowell ML; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2020 May; 95(5):492-496. PubMed ID: 31990410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inheritance in erythropoietic protoporphyria].
    Schmitt C; Ducamp S; Gouya L; Deybach JC; Puy H
    Pathol Biol (Paris); 2010 Oct; 58(5):372-80. PubMed ID: 20850938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical abnormality in erythropoietic protoporphyria: cause and consequences.
    Bloomer JR; Wang Y; Singhal A; Risheg H
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S36-40. PubMed ID: 16819399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria.
    Mirmiran A; Schmitt C; Lefebvre T; Manceau H; Daher R; Oustric V; Poli A; Lacapère JJ; Moulouel B; Puy H; Karim Z; Peoc'h K; Lenglet H; Simonin S; Deybach JC; Nicolas G; Gouya L
    Am J Hum Genet; 2019 Feb; 104(2):341-347. PubMed ID: 30712775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria.
    Halloy F; Iyer PS; Ghidini A; Lysenko V; Barman-Aksözen J; Grubenmann CP; Jucker J; Wildner-Verhey van Wijk N; Ruepp MD; Minder EI; Minder AE; Schneider-Yin X; Theocharides APA; Schümperli D; Hall J
    Cell Chem Biol; 2021 Aug; 28(8):1221-1234.e6. PubMed ID: 33756123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model.
    Lyoumi S; Abitbol M; Rainteau D; Karim Z; Bernex F; Oustric V; Millot S; Lettéron P; Heming N; Guillmot L; Montagutelli X; Berdeaux G; Gouya L; Poupon R; Deybach JC; Beaumont C; Puy H
    Gastroenterology; 2011 Oct; 141(4):1509-19, 1519.e1-3. PubMed ID: 21762662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular genetics of erythropoietic protoporphyria.
    Elder GH; Gouya L; Whatley SD; Puy H; Badminton MN; Deybach JC
    Cell Mol Biol (Noisy-le-grand); 2009 Jul; 55(2):118-26. PubMed ID: 19656460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of protoporphyrin IX in erythrocytes in a case of acquired erythropoietic protoporphyria.
    Heerfordt IM; Fontenete S; Lerche CM; Wulf HC
    Photodiagnosis Photodyn Ther; 2022 Mar; 37():102629. PubMed ID: 34798346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability.
    Barman-Aksözen J; Minder EI; Schubiger C; Biolcati G; Schneider-Yin X
    Blood Cells Mol Dis; 2015 Jan; 54(1):71-7. PubMed ID: 25179834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietic protoporphyria.
    Lecha M; Puy H; Deybach JC
    Orphanet J Rare Dis; 2009 Sep; 4():19. PubMed ID: 19744342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.
    Balwani M; Naik H; Anderson KE; Bissell DM; Bloomer J; Bonkovsky HL; Phillips JD; Overbey JR; Wang B; Singal AK; Liu LU; Desnick RJ
    JAMA Dermatol; 2017 Aug; 153(8):789-796. PubMed ID: 28614581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria.
    Halloy F; Iyer PS; Ćwiek P; Ghidini A; Barman-Aksözen J; Wildner-Verhey van Wijk N; Theocharides APA; Minder EI; Schneider-Yin X; Schümperli D; Hall J
    Nucleic Acids Res; 2020 May; 48(9):4658-4671. PubMed ID: 32313951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.
    Oustric V; Manceau H; Ducamp S; Soaid R; Karim Z; Schmitt C; Mirmiran A; Peoc'h K; Grandchamp B; Beaumont C; Lyoumi S; Moreau-Gaudry F; Guyonnet-Dupérat V; de Verneuil H; Marie J; Puy H; Deybach JC; Gouya L
    Am J Hum Genet; 2014 Apr; 94(4):611-7. PubMed ID: 24680888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.